Skip to main content
2025 Canadian Cardiovascular Congress Main banner

Heart Failure

Interventional Cardiology

Cardiology

Clinical Research

Medical Technology

Canadian Heart Failure Society (CHFS)

Canadian Association of Interventional Cardiology (CAIC)

ACQ

Canadian Cardiovascular Pharmacist Network (CCPN)

CCCN
Session Type: Workshop

156 - HFPEF UPDATE 2025

Thursday, October 23, 2025
3:15pm - 4:15pm ET
Room:301AB

Target Audience: General: All cardiovascular (clinical and research) health professionals, Trainee (clinical), Heart failure specialists

Workshop Description: The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing year over year in western societies, now accounting for more than half of heart failure patients, and hospitalizations for HFpEF have doubled in the last decade. Despite this, clinical recognition of HFpEF remains a challenge, and investigation and management practices vary widely despite recent expert consensus statements, likely explained by a combination of therapeutic inertia, variable availability of expert HFpEF evaluation and differences in reimbursement for proven therapies across the country. As unrecognized or undertreated HFpEF is associated with poor functional capacity and quality of life in addition to increased resource use, there is an urgent need for educational initiatives, such as the HFpEF Update 2025 workshop, to bridge knowledge gaps, generate enthusiasm for the potential of medical and device therapy for HFpEF patients in 2025 and beyond, and to actively engage the cardiovascular community in order to level the playing field by developing local expertise and investigational pathways.

The Workshop Planning Committee, representing a breadth of cardiovascular specialties, has therefore developed a dynamic, interactive program covering essential and up-to-date topics, including new insights into the pathophysiology, diagnosis and phenotyping of HFpEF (Dr Nadia Bouabdallaoui MD PhD, QC, CHFS ACQ, Early Career), the role and best practices for exercise testing in suspected HFpEF patients (Dr Susanna Mak MD PhD, ON, CHFS), an expert review of recent landmark and upcoming pharmaceutical trials in HFpEF (Dr Elizabeth Swiggum MD, BC, CHFS), and a glance at innovative interventional therapies with a potential complementary role for HFpEF patients (Dr Brian J Potter MD SM, QC, CAIC ACQ). Audience engagement will be assured through pre- and post-test polling using the Audience Response System (ARS), as well as a Q&A session moderated by our expert Co-Chair (Harriette Van Spall MD MPH, ON, CHFS). The development committee and panel also included a hospital-based cardiology pharmacist (John Nguyen PharmD, QC) and a community-based nurse practitioner specializing in heart failure (Morgan Krauter NP, ON, CCCN).

This workshop will be of definite interest to general cardiologists, heart failure and interventional specialists, nurses and nurse practitioners, pharmacists, basic and translational scientists, and trainees alike. By the end of the session, participants will have an improved understanding of the pathophysiology and diagnosis of HFpEF, including diagnostic scores, phenotyping and both invasive and non-invasive exercise testing in addition to the latest evidence for both medical and device therapy for HFpEF.

Learning Objectives:

At the end of this session participants will be able to:
  • describe the main HFpEF Phenotypes and name 2 diagnostic scores;
  • appropriately identify patients requiring exercise hemodynamic assessment; and
  • name 3 ongoing Phase-3 medical or device HFpEF trials to look out for.